Global Enzyme Replacement Therapy Market By Drug (Alglucerase alfa, Laronidase, Imiglucerase, Idursulfase, Velaglucerase alfa, Taliglucerase alfa, Asfotase alfa, Galsulfase, Pegademase, Pancreatic Enzymes, Others); By Route of Administration (Oral, Parenteral); By Disease (Gaucher disease, A1AT Deficiency, ADA Deficiency, Fabry, Pompe, Mucopolysaccharidosis – MPS 1, MSP II, MPS IVA, MPS VI, MPS VII, Hurler’s syndrome, Others); By Demography (Adults, Children); By End User (Infusion Centers, Gaucher disease treatment centers, Hospitals and clinics, Others); By Region (U.S., Canada, Mexico, Rest of North America, France, UK, Germany, Spain, Italy, Nordic Countries, Benelux Union, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Rest of Asia Pacific, Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of MEA, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
In terms of revenue, the global enzyme replacement therapy market was valued at US$ 8.2 Bn in 2021, growing at an estimated CAGR of 9% over the forecast period. The cells of the human body are relentlessly working to take care of critical tasks, majority of those go fully unnoticed. Though when there is some sort of issue at the cellular level, the effects are likely to critical and extensive. Enzymes happen to be one such key components of healthy bodily function. These enzymes look after all the interaction with other chemicals that go on inside the human body to bring about specific reactions, like converting complex sugars into ATP. Every time, there is a dysfunction with one’s enzymes, it is likely to have terrible consequences which needs treatments for the lifetime. One such treatment for this lifetime is replacement of the deficient enzymes through a process that is called enzyme replacement therapy. Enzyme replacement therapy (ERT) primarily are a medical treatment where replacement enzymes are granted to patients from chronic conditions that are result of enzyme deficiencies or malfunction. Need for newer ways of treatment that is effective and safe is the reason why the global enzyme replacement therapy market is grow rapidly.
The global enzyme replacement therapy market was unaffected by the COVID-19 pandemic. Newer methods of treatment were sought to fight against the highly infectious virus and this is why demand for enzyme replacement therapy went up.
Drug Outlook
The drug segment of the global enzyme replacement therapy market has been divided into alglucerase alfa, laronidase, imiglucerase, idursulfase, velaglucerase alfa, taliglucerase alfa, asfotase alfa, galsulfase, pegademase, pancreatic enzymes and others. The imiglucerase segment accounts for majority of revenue generated by this market.
Global Enzyme Replacement Therapy Market Revenue & Forecast, (US$ Million), 2022 – 2030
Route of Administration Outlook
On the basis of route of administration, the global enzyme replacement therapy market has been categorised into oral and parenteral. The parenteral segment has been dominating in terms of generating major amount of money for this market. Parenteral drug administration basically is a way of administering drugs not just through the digestive tract. The term parenteral is more commonly used for drugs that are given through injection or infusion. Meanwhile, the enteral route primarily refers to consumption of drugs via mouth.
Disease Outlook
The disease segment of the global enzyme replacement therapy market has been divided into Gaucher disease, A1AT deficiency, ADA deficiency, fabry, pompe, mucopolysaccharidosis, Hurler’s syndrome and others. The mucopolysaccharidosis segment is further bifurcated into MPS 1, MSP II, MPS IVA, MPS VI, and MPS VII. The Gaucher disease segment mints most of the money for this market. In this disease, there is a dysfunction of the glucocerebrosidase enzyme, which breaks down fatty chemicals in the body and converts into a build-up of fatty cells called Gaucher cells, in specific organs.
Demography Outlook
The demography segment of the global enzyme replacement therapy market has been segmented into adults and children. The adults segment dominates in terms of market share as compared to the other segment.
End User Outlook
The end user segment of the global enzyme replacement therapy market has been divided into infusion centers, Gaucher disease treatment centers, hospitals and clinics, and others. The hospitals and clinics segment earns the most for this market. On the other hand, the infusion centers segment is forecasted to see growth at the fastest rate.
Region Outlook
On the basis of region, the global enzyme replacement therapy market has been divided into Latin America, Europe, North America, Asia-Pacific and others. The region of the North America has been generating major chunk of revenue for this market. Highly advanced medical infrastructure in nations like the United States and Canada is the reason why this market is growing in the region.
Competitive Landscape
The report provides both, qualitative and quantitative research of global enzyme replacement therapy market as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contacts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the major players operating in the global enzyme replacement therapy market are listed below:
- AbbVie Inc.
- Amicus Therapeutics, Inc
- BioMarin
- CHIESI Farmaceutici S.p.A.
- Digestive Care, Inc.
- Leadiant Biosciences, Inc.
- Nestle Health Science
- Pfizer Inc.
- Protalix
- Sanofi
- Takeda Pharmaceutical Company Limited
- Other Market Participants
Global Enzyme Replacement Therapy Market
By Drug
- Alglucerase alfa
- Laronidase
- Imiglucerase
- Idursulfase
- Velaglucerase alfa
- Taliglucerase alfa
- Asfotase alfa
- Galsulfase
- Pegademase
- Pancreatic Enzymes
- Others
By Route of Administration
- Oral
- Parenteral
By Disease
- Gaucher disease
- A1AT Deficiency
- ADA Deficiency
- Fabry
- Pompe
- Mucopolysaccharidosis
- MPS 1
- MSP II
- MPS IVA
- MPS VI
- MPS VII
- Hurler’s Syndrome
- Others
By Demography
- Adults
- Children
By End User
- Infusion Centers
- Gaucher disease treatment centers
- Hospitals and clinics
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2020
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Enzyme Replacement Therapy Market
6.
Market
Synopsis:Â Enzyme Replacement Therapy
Market
7.
Enzyme
Replacement Therapy Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Enzyme Replacement Therapy Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Enzyme Replacement Therapy Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Enzyme Replacement
Therapy Market
7.8. PESTEL Analysis
8.
Global
Enzyme Replacement Therapy Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn)
8.2. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Drug
8.2.1. Alglucerase alfa
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2. Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Laronidase
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2. Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Imiglucerase
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Idursulfase
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.2.5. Velaglucerase alfa
8.2.5.1.
Definition
8.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.5.3.
Market
Forecast, 2022 - 2030
8.2.5.4.
Compound
Annual Growth Rate (CAGR)
8.2.5.5.
Regional
Bifurcation
8.2.5.5.1. North America
8.2.5.5.1.1. Market Estimation, 2015 - 2021
8.2.5.5.1.2. Market Forecast, 2022 - 2030
8.2.5.5.2. Europe
8.2.5.5.2.1. Market Estimation, 2015 - 2021
8.2.5.5.2.2. Market Forecast, 2022 - 2030
8.2.5.5.3. Asia Pacific
8.2.5.5.3.1. Market Estimation, 2015 - 2021
8.2.5.5.3.2. Market Forecast, 2022 - 2030
8.2.5.5.4. Middle East and Africa
8.2.5.5.4.1. Market Estimation, 2015 - 2021
8.2.5.5.4.2. Market Forecast, 2022 - 2030
8.2.5.5.5. Latin America
8.2.5.5.5.1. Market Estimation, 2015 - 2021
8.2.5.5.5.2. Market Forecast, 2022 - 2030
8.2.6. Taliglucerase alfa
8.2.6.1.
Definition
8.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.6.3.
Market
Forecast, 2022 - 2030
8.2.6.4.
Compound
Annual Growth Rate (CAGR)
8.2.6.5.
Regional
Bifurcation
8.2.6.5.1. North America
8.2.6.5.1.1. Market Estimation, 2015 - 2021
8.2.6.5.1.2. Market Forecast, 2022 - 2030
8.2.6.5.2. Europe
8.2.6.5.2.1. Market Estimation, 2015 - 2021
8.2.6.5.2.2. Market Forecast, 2022 - 2030
8.2.6.5.3. Asia Pacific
8.2.6.5.3.1. Market Estimation, 2015 - 2021
8.2.6.5.3.2. Market Forecast, 2022 - 2030
8.2.6.5.4. Middle East and Africa
8.2.6.5.4.1. Market Estimation, 2015 - 2021
8.2.6.5.4.2. Market Forecast, 2022 - 2030
8.2.6.5.5. Latin America
8.2.6.5.5.1. Market Estimation, 2015 - 2021
8.2.6.5.5.2. Market Forecast, 2022 - 2030
8.2.7. Asfotase alfa
8.2.7.1.
Definition
8.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.7.3.
Market
Forecast, 2022 - 2030
8.2.7.4.
Compound
Annual Growth Rate (CAGR)
8.2.7.5.
Regional
Bifurcation
8.2.7.5.1. North America
8.2.7.5.1.1. Market Estimation, 2015 - 2021
8.2.7.5.1.2. Market Forecast, 2022 - 2030
8.2.7.5.2. Europe
8.2.7.5.2.1. Market Estimation, 2015 - 2021
8.2.7.5.2.2. Market Forecast, 2022 - 2030
8.2.7.5.3. Asia Pacific
8.2.7.5.3.1. Market Estimation, 2015 - 2021
8.2.7.5.3.2. Market Forecast, 2022 - 2030
8.2.7.5.4. Middle East and Africa
8.2.7.5.4.1. Market Estimation, 2015 - 2021
8.2.7.5.4.2. Market Forecast, 2022 - 2030
8.2.7.5.5. Latin America
8.2.7.5.5.1. Market Estimation, 2015 - 2021
8.2.7.5.5.2. Market Forecast, 2022 - 2030
8.2.8. Galsulfase
8.2.8.1.
Definition
8.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.8.3.
Market
Forecast, 2022 - 2030
8.2.8.4.
Compound
Annual Growth Rate (CAGR)
8.2.8.5.
Regional
Bifurcation
8.2.8.5.1. North America
8.2.8.5.1.1. Market Estimation, 2015 - 2021
8.2.8.5.1.2. Market Forecast, 2022 - 2030
8.2.8.5.2. Europe
8.2.8.5.2.1. Market Estimation, 2015 - 2021
8.2.8.5.2.2. Market Forecast, 2022 - 2030
8.2.8.5.3. Asia Pacific
8.2.8.5.3.1. Market Estimation, 2015 - 2021
8.2.8.5.3.2. Market Forecast, 2022 - 2030
8.2.8.5.4. Middle East and Africa
8.2.8.5.4.1. Market Estimation, 2015 - 2021
8.2.8.5.4.2. Market Forecast, 2022 - 2030
8.2.8.5.5. Latin America
8.2.8.5.5.1. Market Estimation, 2015 - 2021
8.2.8.5.5.2. Market Forecast, 2022 - 2030
8.2.9. Pegademase
8.2.9.1.
Definition
8.2.9.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.9.3.
Market
Forecast, 2022 - 2030
8.2.9.4.
Compound
Annual Growth Rate (CAGR)
8.2.9.5.
Regional
Bifurcation
8.2.9.5.1. North America
8.2.9.5.1.1. Market Estimation, 2015 - 2021
8.2.9.5.1.2. Market Forecast, 2022 - 2030
8.2.9.5.2. Europe
8.2.9.5.2.1. Market Estimation, 2015 - 2021
8.2.9.5.2.2. Market Forecast, 2022 - 2030
8.2.9.5.3. Asia Pacific
8.2.9.5.3.1. Market Estimation, 2015 - 2021
8.2.9.5.3.2. Market Forecast, 2022 - 2030
8.2.9.5.4. Middle East and Africa
8.2.9.5.4.1. Market Estimation, 2015 - 2021
8.2.9.5.4.2. Market Forecast, 2022 - 2030
8.2.9.5.5. Latin America
8.2.9.5.5.1. Market Estimation, 2015 - 2021
8.2.9.5.5.2. Market Forecast, 2022 - 2030
8.2.10. Pancreatic Enzymes
8.2.10.1.
Definition
8.2.10.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.10.3.
Market
Forecast, 2022 - 2030
8.2.10.4.
Compound
Annual Growth Rate (CAGR)
8.2.10.5.
Regional
Bifurcation
8.2.10.5.1. North America
8.2.10.5.1.1. Market Estimation, 2015 - 2021
8.2.10.5.1.2. Market Forecast, 2022 - 2030
8.2.10.5.2. Europe
8.2.10.5.2.1. Market Estimation, 2015 - 2021
8.2.10.5.2.2. Market Forecast, 2022 - 2030
8.2.10.5.3. Asia Pacific
8.2.10.5.3.1. Market Estimation, 2015 - 2021
8.2.10.5.3.2. Market Forecast, 2022 - 2030
8.2.10.5.4. Middle East and Africa
8.2.10.5.4.1. Market Estimation, 2015 - 2021
8.2.10.5.4.2. Market Forecast, 2022 - 2030
8.2.10.5.5. Latin America
8.2.10.5.5.1. Market Estimation, 2015 - 2021
8.2.10.5.5.2. Market Forecast, 2022 - 2030
8.2.11. Others
8.2.11.1.
Definition
8.2.11.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.11.3.
Market
Forecast, 2022 - 2030
8.2.11.4.
Compound
Annual Growth Rate (CAGR)
8.2.11.5.
Regional
Bifurcation
8.2.11.5.1. North America
8.2.11.5.1.1. Market Estimation, 2015 - 2021
8.2.11.5.1.2. Market Forecast, 2022 - 2030
8.2.11.5.2. Europe
8.2.11.5.2.1. Market Estimation, 2015 - 2021
8.2.11.5.2.2. Market Forecast, 2022 - 2030
8.2.11.5.3. Asia Pacific
8.2.11.5.3.1. Market Estimation, 2015 - 2021
8.2.11.5.3.2. Market Forecast, 2022 - 2030
8.2.11.5.4. Middle East and Africa
8.2.11.5.4.1. Market Estimation, 2015 - 2021
8.2.11.5.4.2. Market Forecast, 2022 - 2030
8.2.11.5.5. Latin America
8.2.11.5.5.1. Market Estimation, 2015 - 2021
8.2.11.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Drug
9.
Global
Enzyme Replacement Therapy Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
9.2.1. Oral
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Parenteral
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Route of Administration
10. Global Enzyme Replacement Therapy Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Disease
10.2.1. Gaucher Disease
10.2.1.1.
Definition
10.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.1.3.
Market
Forecast, 2022 - 2030
10.2.1.4.
Compound
Annual Growth Rate (CAGR)
10.2.1.5.
Regional
Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Â A1AT
Deficiency
10.2.2.1.
Definition
10.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.2.3.
Market
Forecast, 2022 - 2030
10.2.2.4.
Compound
Annual Growth Rate (CAGR)
10.2.2.5.
Regional
Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. ADA Deficiency
10.2.3.1.
Definition
10.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.3.3.
Market
Forecast, 2022 - 2030
10.2.3.4.
Compound
Annual Growth Rate (CAGR)
10.2.3.5.
Regional
Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.2.4. Fabry
10.2.4.1.
Definition
10.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.4.3.
Market
Forecast, 2022 - 2030
10.2.4.4.
Compound
Annual Growth Rate (CAGR)
10.2.4.5.
Regional
Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market Estimation, 2015 - 2021
10.2.4.5.1.2. Market Forecast, 2022 - 2030
10.2.4.5.2. Europe
10.2.4.5.2.1. Market Estimation, 2015 - 2021
10.2.4.5.2.2. Market Forecast, 2022 - 2030
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market Estimation, 2015 - 2021
10.2.4.5.3.2. Market Forecast, 2022 - 2030
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market Estimation, 2015 - 2021
10.2.4.5.4.2. Market Forecast, 2022 - 2030
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market Estimation, 2015 - 2021
10.2.4.5.5.2. Market Forecast, 2022 - 2030
10.2.5. Â Pompe
10.2.5.1.
Definition
10.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.5.3.
Market
Forecast, 2022 - 2030
10.2.5.4.
Compound
Annual Growth Rate (CAGR)
10.2.5.5.
Regional
Bifurcation
10.2.5.5.1. North America
10.2.5.5.1.1. Market Estimation, 2015 - 2021
10.2.5.5.1.2. Market Forecast, 2022 - 2030
10.2.5.5.2. Europe
10.2.5.5.2.1. Market Estimation, 2015 - 2021
10.2.5.5.2.2. Market Forecast, 2022 - 2030
10.2.5.5.3. Asia Pacific
10.2.5.5.3.1. Market Estimation, 2015 - 2021
10.2.5.5.3.2. Market Forecast, 2022 - 2030
10.2.5.5.4. Middle East and Africa
10.2.5.5.4.1. Market Estimation, 2015 - 2021
10.2.5.5.4.2. Market Forecast, 2022 - 2030
10.2.5.5.5. Latin America
10.2.5.5.5.1. Market Estimation, 2015 - 2021
10.2.5.5.5.2. Market Forecast, 2022 - 2030
10.2.6. Mucopolysaccharidosis (Definition, Market
Estimation and Penetration, 2015 - 2021, Market Estimation (2015 - 2021),
Market Forecast (2022 - 2030), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on MPS 1, MSP II, MPS IVA, MPS VI, MPS VII)
10.2.6.1.
MPS 1
10.2.6.2.
MSP II
10.2.6.3.
MPS IVA
10.2.6.4.
MPS VI
10.2.6.5.
MPS VII
10.2.7. Hurler’s Syndrome
10.2.7.1.
Definition
10.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.7.3.
Market
Forecast, 2022 - 2030
10.2.7.4.
Compound
Annual Growth Rate (CAGR)
10.2.7.5.
Regional
Bifurcation
10.2.7.5.1. North America
10.2.7.5.1.1. Market Estimation, 2015 - 2021
10.2.7.5.1.2. Market Forecast, 2022 - 2030
10.2.7.5.2. Europe
10.2.7.5.2.1. Market Estimation, 2015 - 2021
10.2.7.5.2.2. Market Forecast, 2022 - 2030
10.2.7.5.3. Asia Pacific
10.2.7.5.3.1. Market Estimation, 2015 - 2021
10.2.7.5.3.2. Market Forecast, 2022 - 2030
10.2.7.5.4. Middle East and Africa
10.2.7.5.4.1. Market Estimation, 2015 - 2021
10.2.7.5.4.2. Market Forecast, 2022 - 2030
10.2.7.5.5. Latin America
10.2.7.5.5.1. Market Estimation, 2015 - 2021
10.2.7.5.5.2. Market Forecast, 2022 - 2030
10.2.8. Others
10.2.8.1.
Definition
10.2.8.2.
Market
Estimation and Penetration, 2015 - 2021
10.2.8.3.
Market
Forecast, 2022 - 2030
10.2.8.4.
Compound
Annual Growth Rate (CAGR)
10.2.8.5.
Regional
Bifurcation
10.2.8.5.1. North America
10.2.8.5.1.1. Market Estimation, 2015 - 2021
10.2.8.5.1.2. Market Forecast, 2022 - 2030
10.2.8.5.2. Europe
10.2.8.5.2.1. Market Estimation, 2015 - 2021
10.2.8.5.2.2. Market Forecast, 2022 - 2030
10.2.8.5.3. Asia Pacific
10.2.8.5.3.1. Market Estimation, 2015 - 2021
10.2.8.5.3.2. Market Forecast, 2022 - 2030
10.2.8.5.4. Middle East and Africa
10.2.8.5.4.1. Market Estimation, 2015 - 2021
10.2.8.5.4.2. Market Forecast, 2022 - 2030
10.2.8.5.5. Latin America
10.2.8.5.5.1. Market Estimation, 2015 - 2021
10.2.8.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By Disease
11. Global Enzyme Replacement Therapy Market
Analysis and Forecasts, 2022 – 2030
11.1. Overview
11.2. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Demography
11.2.1. Adults
11.2.1.1.
Definition
11.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.1.3.
Market
Forecast, 2022 - 2030
11.2.1.4.
Compound
Annual Growth Rate (CAGR)
11.2.1.5.
Regional
Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market Estimation, 2015 - 2021
11.2.1.5.1.2. Market Forecast, 2022 - 2030
11.2.1.5.2. Europe
11.2.1.5.2.1. Market Estimation, 2015 - 2021
11.2.1.5.2.2. Market Forecast, 2022 - 2030
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market Estimation, 2015 - 2021
11.2.1.5.3.2. Market Forecast, 2022 - 2030
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market Estimation, 2015 - 2021
11.2.1.5.4.2. Market Forecast, 2022 - 2030
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market Estimation, 2015 - 2021
11.2.1.5.5.2. Market Forecast, 2022 - 2030
11.2.2. Children
11.2.2.1.
Definition
11.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
11.2.2.3.
Market
Forecast, 2022 - 2030
11.2.2.4.
Compound
Annual Growth Rate (CAGR)
11.2.2.5.
Regional
Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market Estimation, 2015 - 2021
11.2.2.5.1.2. Market Forecast, 2022 - 2030
11.2.2.5.2. Europe
11.2.2.5.2.1. Market Estimation, 2015 - 2021
11.2.2.5.2.2. Market Forecast, 2022 - 2030
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market Estimation, 2015 - 2021
11.2.2.5.3.2. Market Forecast, 2022 - 2030
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market Estimation, 2015 - 2021
11.2.2.5.4.2. Market Forecast, 2022 - 2030
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market Estimation, 2015 - 2021
11.2.2.5.5.2. Market Forecast, 2022 - 2030
11.3. Key Segment for Channeling Investments
11.3.1. By Demography
12. Global Enzyme Replacement Therapy Market
Analysis and Forecasts, 2022 – 2030
12.1. Overview
12.2. Global Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By End User
12.2.1. Infusion Centers
12.2.1.1.
Definition
12.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.1.3.
Market
Forecast, 2022 - 2030
12.2.1.4.
Compound
Annual Growth Rate (CAGR)
12.2.1.5.
Regional
Bifurcation
12.2.1.5.1. North America
12.2.1.5.1.1. Market Estimation, 2015 - 2021
12.2.1.5.1.2. Market Forecast, 2022 - 2030
12.2.1.5.2. Europe
12.2.1.5.2.1. Market Estimation, 2015 - 2021
12.2.1.5.2.2. Market Forecast, 2022 - 2030
12.2.1.5.3. Asia Pacific
12.2.1.5.3.1. Market Estimation, 2015 - 2021
12.2.1.5.3.2. Market Forecast, 2022 - 2030
12.2.1.5.4. Middle East and Africa
12.2.1.5.4.1. Market Estimation, 2015 - 2021
12.2.1.5.4.2. Market Forecast, 2022 - 2030
12.2.1.5.5. Latin America
12.2.1.5.5.1. Market Estimation, 2015 - 2021
12.2.1.5.5.2. Market Forecast, 2022 - 2030
12.2.2. Gaucher Disease Treatment Centers
12.2.2.1.
Definition
12.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.2.3.
Market
Forecast, 2022 - 2030
12.2.2.4.
Compound
Annual Growth Rate (CAGR)
12.2.2.5.
Regional
Bifurcation
12.2.2.5.1. North America
12.2.2.5.1.1. Market Estimation, 2015 - 2021
12.2.2.5.1.2. Market Forecast, 2022 - 2030
12.2.2.5.2. Europe
12.2.2.5.2.1. Market Estimation, 2015 - 2021
12.2.2.5.2.2. Market Forecast, 2022 - 2030
12.2.2.5.3. Asia Pacific
12.2.2.5.3.1. Market Estimation, 2015 - 2021
12.2.2.5.3.2. Market Forecast, 2022 - 2030
12.2.2.5.4. Middle East and Africa
12.2.2.5.4.1. Market Estimation, 2015 - 2021
12.2.2.5.4.2. Market Forecast, 2022 - 2030
12.2.2.5.5. Latin America
12.2.2.5.5.1. Market Estimation, 2015 - 2021
12.2.2.5.5.2. Market Forecast, 2022 - 2030
12.2.3. Hospitals and Clinics
12.2.3.1.
Definition
12.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.3.3.
Market
Forecast, 2022 - 2030
12.2.3.4.
Compound
Annual Growth Rate (CAGR)
12.2.3.5.
Regional
Bifurcation
12.2.3.5.1. North America
12.2.3.5.1.1. Market Estimation, 2015 - 2021
12.2.3.5.1.2. Market Forecast, 2022 - 2030
12.2.3.5.2. Europe
12.2.3.5.2.1. Market Estimation, 2015 - 2021
12.2.3.5.2.2. Market Forecast, 2022 - 2030
12.2.3.5.3. Asia Pacific
12.2.3.5.3.1. Market Estimation, 2015 - 2021
12.2.3.5.3.2. Market Forecast, 2022 - 2030
12.2.3.5.4. Middle East and Africa
12.2.3.5.4.1. Market Estimation, 2015 - 2021
12.2.3.5.4.2. Market Forecast, 2022 - 2030
12.2.3.5.5. Latin America
12.2.3.5.5.1. Market Estimation, 2015 - 2021
12.2.3.5.5.2. Market Forecast, 2022 - 2030
12.2.4. Others
12.2.4.1.
Definition
12.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
12.2.4.3.
Market
Forecast, 2022 - 2030
12.2.4.4.
Compound
Annual Growth Rate (CAGR)
12.2.4.5.
Regional
Bifurcation
12.2.4.5.1. North America
12.2.4.5.1.1. Market Estimation, 2015 - 2021
12.2.4.5.1.2. Market Forecast, 2022 - 2030
12.2.4.5.2. Europe
12.2.4.5.2.1. Market Estimation, 2015 - 2021
12.2.4.5.2.2. Market Forecast, 2022 - 2030
12.2.4.5.3. Asia Pacific
12.2.4.5.3.1. Market Estimation, 2015 - 2021
12.2.4.5.3.2. Market Forecast, 2022 - 2030
12.2.4.5.4. Middle East and Africa
12.2.4.5.4.1. Market Estimation, 2015 - 2021
12.2.4.5.4.2. Market Forecast, 2022 - 2030
12.2.4.5.5. Latin America
12.2.4.5.5.1. Market Estimation, 2015 - 2021
12.2.4.5.5.2. Market Forecast, 2022 - 2030
12.3. Key Segment for Channeling Investments
12.3.1. By End User
13. North America Enzyme Replacement Therapy
Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn)
13.2. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
13.2.1. Alglucerase alfa
13.2.2. Laronidase
13.2.3. Imiglucerase
13.2.4. Idursulfase
13.2.5. Velaglucerase alfa
13.2.6. Taliglucerase alfa
13.2.7. Asfotase alfa
13.2.8. Galsulfase
13.2.9. Pegademase
13.2.10. Pancreatic Enzymes
13.2.11. Others
13.3. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
13.3.1. Oral
13.3.2. Parenteral
13.4. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Disease
13.4.1. Gaucher Disease
13.4.2. Â A1AT
Deficiency
13.4.3. ADA Deficiency
13.4.4. Fabry
13.4.5. Â Pompe
13.4.6. Mucopolysaccharidosis
13.4.6.1.
MPS 1
13.4.6.2.
MSP II
13.4.6.3.
MPS IVA
13.4.6.4.
MPS VI
13.4.6.5.
MPS VII
13.4.7. Hurler’s Syndrome
13.4.8. Others
13.5. North America Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Demography
13.5.1. Adults
13.5.2. Children
13.6. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By End User
13.6.1. Infusion Centers
13.6.2. Gaucher Disease Treatment Centers
13.6.3. Hospitals and Clinics
13.6.4. Others
13.7. North America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
13.7.1. U.S
13.7.1.1.
U.S
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.1.1.1. Alglucerase alfa
13.7.1.1.2. Laronidase
13.7.1.1.3. Imiglucerase
13.7.1.1.4. Idursulfase
13.7.1.1.5. Velaglucerase alfa
13.7.1.1.6. Taliglucerase alfa
13.7.1.1.7. Asfotase alfa
13.7.1.1.8. Galsulfase
13.7.1.1.9. Pegademase
13.7.1.1.10. Pancreatic Enzymes
13.7.1.1.11. Others
13.7.1.2.
U.S
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.1.2.1. Oral
13.7.1.2.2. Parenteral
13.7.1.3.
U.S
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
13.7.1.3.1. Gaucher Disease
13.7.1.3.2. Â A1AT
Deficiency
13.7.1.3.3. ADA Deficiency
13.7.1.3.4. Fabry
13.7.1.3.5. Â Pompe
13.7.1.3.6. Mucopolysaccharidosis
13.7.1.3.6.1. MPS 1
13.7.1.3.6.2. MSP II
13.7.1.3.6.3. MPS IVA
13.7.1.3.6.4. MPS VI
13.7.1.3.6.5. MPS VII
13.7.1.3.7. Hurler’s Syndrome
13.7.1.3.8. Others
13.7.1.4.
U.S
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
13.7.1.4.1. Adults
13.7.1.4.2. Children
13.7.1.5.
U.S
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
13.7.1.5.1. Infusion Centers
13.7.1.5.2. Gaucher Disease Treatment Centers
13.7.1.5.3. Hospitals and Clinics
13.7.1.5.4. Others
13.7.2. Canada
13.7.2.1.
Canada
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.2.1.1. Alglucerase alfa
13.7.2.1.2. Laronidase
13.7.2.1.3. Imiglucerase
13.7.2.1.4. Idursulfase
13.7.2.1.5. Velaglucerase alfa
13.7.2.1.6. Taliglucerase alfa
13.7.2.1.7. Asfotase alfa
13.7.2.1.8. Galsulfase
13.7.2.1.9. Pegademase
13.7.2.1.10. Pancreatic Enzymes
13.7.2.1.11. Others
13.7.2.2.
Canada
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.2.2.1. Oral
13.7.2.2.2. Parenteral
13.7.2.3.
Canada
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
13.7.2.3.1. Gaucher Disease
13.7.2.3.2. Â A1AT
Deficiency
13.7.2.3.3. ADA Deficiency
13.7.2.3.4. Fabry
13.7.2.3.5. Â Pompe
13.7.2.3.6. Mucopolysaccharidosis
13.7.2.3.6.1. MPS 1
13.7.2.3.6.2. MSP II
13.7.2.3.6.3. MPS IVA
13.7.2.3.6.4. MPS VI
13.7.2.3.6.5. MPS VII
13.7.2.3.7. Hurler’s Syndrome
13.7.2.3.8. Others
13.7.2.4.
Canada
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
13.7.2.4.1. Adults
13.7.2.4.2. Children
13.7.2.5.
Canada
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
13.7.2.5.1. Infusion Centers
13.7.2.5.2. Gaucher Disease Treatment Centers
13.7.2.5.3. Hospitals and Clinics
13.7.2.5.4. Others
13.7.3. Mexico
13.7.3.1.
Mexico Enzyme
Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
13.7.3.1.1. Alglucerase alfa
13.7.3.1.2. Laronidase
13.7.3.1.3. Imiglucerase
13.7.3.1.4. Idursulfase
13.7.3.1.5. Velaglucerase alfa
13.7.3.1.6. Taliglucerase alfa
13.7.3.1.7. Asfotase alfa
13.7.3.1.8. Galsulfase
13.7.3.1.9. Pegademase
13.7.3.1.10. Pancreatic Enzymes
13.7.3.1.11. Others
13.7.3.2.
Mexico
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
13.7.3.2.1. Oral
13.7.3.2.2. Parenteral
13.7.3.3.
Mexico
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
13.7.3.3.1. Gaucher Disease
13.7.3.3.2. Â A1AT
Deficiency
13.7.3.3.3. ADA Deficiency
13.7.3.3.4. Fabry
13.7.3.3.5. Â Pompe
13.7.3.3.6. Mucopolysaccharidosis
13.7.3.3.6.1. MPS 1
13.7.3.3.6.2. MSP II
13.7.3.3.6.3. MPS IVA
13.7.3.3.6.4. MPS VI
13.7.3.3.6.5. MPS VII
13.7.3.3.7. Hurler’s Syndrome
13.7.3.3.8. Others
13.7.3.4.
Mexico
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
13.7.3.4.1. Adults
13.7.3.4.2. Children
13.7.3.5.
Mexico
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
13.7.3.5.1. Infusion Centers
13.7.3.5.2. Gaucher Disease Treatment Centers
13.7.3.5.3. Hospitals and Clinics
13.7.3.5.4. Others
13.7.4. Rest of North America
13.7.4.1.
Rest of
North America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Drug
13.7.4.1.1. Alglucerase alfa
13.7.4.1.2. Laronidase
13.7.4.1.3. Imiglucerase
13.7.4.1.4. Idursulfase
13.7.4.1.5. Velaglucerase alfa
13.7.4.1.6. Taliglucerase alfa
13.7.4.1.7. Asfotase alfa
13.7.4.1.8. Galsulfase
13.7.4.1.9. Pegademase
13.7.4.1.10. Pancreatic Enzymes
13.7.4.1.11. Others
13.7.4.2.
Rest of
North America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
13.7.4.2.1. Oral
13.7.4.2.2. Parenteral
13.7.4.3.
Rest of
North America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Disease
13.7.4.3.1. Gaucher Disease
13.7.4.3.2. Â A1AT
Deficiency
13.7.4.3.3. ADA Deficiency
13.7.4.3.4. Fabry
13.7.4.3.5. Â Pompe
13.7.4.3.6. Mucopolysaccharidosis
13.7.4.3.6.1. MPS 1
13.7.4.3.6.2. MSP II
13.7.4.3.6.3. MPS IVA
13.7.4.3.6.4. MPS VI
13.7.4.3.6.5. MPS VII
13.7.4.3.7. Hurler’s Syndrome
13.7.4.3.8. Others
13.7.4.4.
Rest of
North America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Demography
13.7.4.4.1. Adults
13.7.4.4.2. Children
13.7.4.5.
Rest of
North America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By End User
13.7.4.5.1. Infusion Centers
13.7.4.5.2. Gaucher Disease Treatment Centers
13.7.4.5.3. Hospitals and Clinics
13.7.4.5.4. Others
13.8. Key Segment for Channeling Investments
13.8.1. By Country
13.8.2. By Drug
13.8.3. By Route of Administration
13.8.4. By Disease
13.8.5. By Demography
13.8.6. By End User
14. Europe Enzyme Replacement Therapy Market
Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn)
14.2. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Drug
14.2.1. Alglucerase alfa
14.2.2. Laronidase
14.2.3. Imiglucerase
14.2.4. Idursulfase
14.2.5. Velaglucerase alfa
14.2.6. Taliglucerase alfa
14.2.7. Asfotase alfa
14.2.8. Galsulfase
14.2.9. Pegademase
14.2.10. Pancreatic Enzymes
14.2.11. Others
14.3. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Route of Administration
14.3.1. Oral
14.3.2. Parenteral
14.4. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Disease
14.4.1. Gaucher Disease
14.4.2. Â A1AT
Deficiency
14.4.3. ADA Deficiency
14.4.4. Fabry
14.4.5. Â Pompe
14.4.6. Mucopolysaccharidosis
14.4.6.1.
MPS 1
14.4.6.2.
MSP II
14.4.6.3.
MPS IVA
14.4.6.4.
MPS VI
14.4.6.5.
MPS VII
14.4.7. Hurler’s Syndrome
14.4.8. Others
14.5. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Demography
14.5.1. Adults
14.5.2. Children
14.6. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By End User
14.6.1. Infusion Centers
14.6.2. Gaucher Disease Treatment Centers
14.6.3. Hospitals and Clinics
14.6.4. Others
14.7. Europe Enzyme Replacement Therapy Market
Revenue (US$ Mn) and Forecasts, By Country
14.7.1. France
14.7.1.1.
France
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.1.1.1. Alglucerase alfa
14.7.1.1.2. Laronidase
14.7.1.1.3. Imiglucerase
14.7.1.1.4. Idursulfase
14.7.1.1.5. Velaglucerase alfa
14.7.1.1.6. Taliglucerase alfa
14.7.1.1.7. Asfotase alfa
14.7.1.1.8. Galsulfase
14.7.1.1.9. Pegademase
14.7.1.1.10. Pancreatic Enzymes
14.7.1.1.11. Others
14.7.1.2.
France
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.1.2.1. Oral
14.7.1.2.2. Parenteral
14.7.1.3.
France
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
14.7.1.3.1. Gaucher Disease
14.7.1.3.2. Â A1AT
Deficiency
14.7.1.3.3. ADA Deficiency
14.7.1.3.4. Fabry
14.7.1.3.5. Â Pompe
14.7.1.3.6. Mucopolysaccharidosis
14.7.1.3.6.1. MPS 1
14.7.1.3.6.2. MSP II
14.7.1.3.6.3. MPS IVA
14.7.1.3.6.4. MPS VI
14.7.1.3.6.5. MPS VII
14.7.1.3.7. Hurler’s Syndrome
14.7.1.3.8. Others
14.7.1.4.
France
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
14.7.1.4.1. Adults
14.7.1.4.2. Children
14.7.1.5.
France
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
14.7.1.5.1. Infusion Centers
14.7.1.5.2. Gaucher Disease Treatment Centers
14.7.1.5.3. Hospitals and Clinics
14.7.1.5.4. Others
14.7.2. The UK
14.7.2.1.
The UK
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.2.1.1. Alglucerase alfa
14.7.2.1.2. Laronidase
14.7.2.1.3. Imiglucerase
14.7.2.1.4. Idursulfase
14.7.2.1.5. Velaglucerase alfa
14.7.2.1.6. Taliglucerase alfa
14.7.2.1.7. Asfotase alfa
14.7.2.1.8. Galsulfase
14.7.2.1.9. Pegademase
14.7.2.1.10. Pancreatic Enzymes
14.7.2.1.11. Others
14.7.2.2.
The UK
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.2.2.1. Oral
14.7.2.2.2. Parenteral
14.7.2.3.
The UK
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
14.7.2.3.1. Gaucher Disease
14.7.2.3.2. Â A1AT
Deficiency
14.7.2.3.3. ADA Deficiency
14.7.2.3.4. Fabry
14.7.2.3.5. Â Pompe
14.7.2.3.6. Mucopolysaccharidosis
14.7.2.3.6.1. MPS 1
14.7.2.3.6.2. MSP II
14.7.2.3.6.3. MPS IVA
14.7.2.3.6.4. MPS VI
14.7.2.3.6.5. MPS VII
14.7.2.3.7. Hurler’s Syndrome
14.7.2.3.8. Others
14.7.2.4.
The UK
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
14.7.2.4.1. Adults
14.7.2.4.2. Children
14.7.2.5.
The UK
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
14.7.2.5.1. Infusion Centers
14.7.2.5.2. Gaucher Disease Treatment Centers
14.7.2.5.3. Hospitals and Clinics
14.7.2.5.4. Others
14.7.3. Spain
14.7.3.1.
Spain
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.3.1.1. Alglucerase alfa
14.7.3.1.2. Laronidase
14.7.3.1.3. Imiglucerase
14.7.3.1.4. Idursulfase
14.7.3.1.5. Velaglucerase alfa
14.7.3.1.6. Taliglucerase alfa
14.7.3.1.7. Asfotase alfa
14.7.3.1.8. Galsulfase
14.7.3.1.9. Pegademase
14.7.3.1.10. Pancreatic Enzymes
14.7.3.1.11. Others
14.7.3.2.
Spain
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.3.2.1. Oral
14.7.3.2.2. Parenteral
14.7.3.3.
Spain
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
14.7.3.3.1. Gaucher Disease
14.7.3.3.2. Â A1AT
Deficiency
14.7.3.3.3. ADA Deficiency
14.7.3.3.4. Fabry
14.7.3.3.5. Â Pompe
14.7.3.3.6. Mucopolysaccharidosis
14.7.3.3.6.1. MPS 1
14.7.3.3.6.2. MSP II
14.7.3.3.6.3. MPS IVA
14.7.3.3.6.4. MPS VI
14.7.3.3.6.5. MPS VII
14.7.3.3.7. Hurler’s Syndrome
14.7.3.3.8. Others
14.7.3.4.
Spain
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
14.7.3.4.1. Adults
14.7.3.4.2. Children
14.7.3.5.
Spain
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
14.7.3.5.1. Infusion Centers
14.7.3.5.2. Gaucher Disease Treatment Centers
14.7.3.5.3. Hospitals and Clinics
14.7.3.5.4. Others
14.7.4. Germany
14.7.4.1.
Germany
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.4.1.1. Alglucerase alfa
14.7.4.1.2. Laronidase
14.7.4.1.3. Imiglucerase
14.7.4.1.4. Idursulfase
14.7.4.1.5. Velaglucerase alfa
14.7.4.1.6. Taliglucerase alfa
14.7.4.1.7. Asfotase alfa
14.7.4.1.8. Galsulfase
14.7.4.1.9. Pegademase
14.7.4.1.10. Pancreatic Enzymes
14.7.4.1.11. Others
14.7.4.2.
Germany
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.4.2.1. Oral
14.7.4.2.2. Parenteral
14.7.4.3.
Germany
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
14.7.4.3.1. Gaucher Disease
14.7.4.3.2. Â A1AT
Deficiency
14.7.4.3.3. ADA Deficiency
14.7.4.3.4. Fabry
14.7.4.3.5. Â Pompe
14.7.4.3.6. Mucopolysaccharidosis
14.7.4.3.6.1. MPS 1
14.7.4.3.6.2. MSP II
14.7.4.3.6.3. MPS IVA
14.7.4.3.6.4. MPS VI
14.7.4.3.6.5. MPS VII
14.7.4.3.7. Hurler’s Syndrome
14.7.4.3.8. Others
14.7.4.4.
Germany
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
14.7.4.4.1. Adults
14.7.4.4.2. Children
14.7.4.5.
Germany
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
14.7.4.5.1. Infusion Centers
14.7.4.5.2. Gaucher Disease Treatment Centers
14.7.4.5.3. Hospitals and Clinics
14.7.4.5.4. Others
14.7.5. Italy
14.7.5.1.
Italy
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.5.1.1. Alglucerase alfa
14.7.5.1.2. Laronidase
14.7.5.1.3. Imiglucerase
14.7.5.1.4. Idursulfase
14.7.5.1.5. Velaglucerase alfa
14.7.5.1.6. Taliglucerase alfa
14.7.5.1.7. Asfotase alfa
14.7.5.1.8. Galsulfase
14.7.5.1.9. Pegademase
14.7.5.1.10. Pancreatic Enzymes
14.7.5.1.11. Others
14.7.5.2.
Italy
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
14.7.5.2.1. Oral
14.7.5.2.2. Parenteral
14.7.5.3.
Italy
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
14.7.5.3.1. Gaucher Disease
14.7.5.3.2. Â A1AT
Deficiency
14.7.5.3.3. ADA Deficiency
14.7.5.3.4. Fabry
14.7.5.3.5. Â Pompe
14.7.5.3.6. Mucopolysaccharidosis
14.7.5.3.6.1. MPS 1
14.7.5.3.6.2. MSP II
14.7.5.3.6.3. MPS IVA
14.7.5.3.6.4. MPS VI
14.7.5.3.6.5. MPS VII
14.7.5.3.7. Hurler’s Syndrome
14.7.5.3.8. Others
14.7.5.4.
Italy
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
14.7.5.4.1. Adults
14.7.5.4.2. Children
14.7.5.5.
Italy
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
14.7.5.5.1. Infusion Centers
14.7.5.5.2. Gaucher Disease Treatment Centers
14.7.5.5.3. Hospitals and Clinics
14.7.5.5.4. Others
14.7.6. Nordic Countries
14.7.6.1.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
14.7.6.1.1. Alglucerase alfa
14.7.6.1.2. Laronidase
14.7.6.1.3. Imiglucerase
14.7.6.1.4. Idursulfase
14.7.6.1.5. Velaglucerase alfa
14.7.6.1.6. Taliglucerase alfa
14.7.6.1.7. Asfotase alfa
14.7.6.1.8. Galsulfase
14.7.6.1.9. Pegademase
14.7.6.1.10. Pancreatic Enzymes
14.7.6.1.11. Others
14.7.6.2.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.6.2.1. Oral
14.7.6.2.2. Parenteral
14.7.6.3.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
14.7.6.3.1. Gaucher Disease
14.7.6.3.2. Â A1AT
Deficiency
14.7.6.3.3. ADA Deficiency
14.7.6.3.4. Fabry
14.7.6.3.5. Â Pompe
14.7.6.3.6. Mucopolysaccharidosis
14.7.6.3.6.1. MPS 1
14.7.6.3.6.2. MSP II
14.7.6.3.6.3. MPS IVA
14.7.6.3.6.4. MPS VI
14.7.6.3.6.5. MPS VII
14.7.6.3.7. Hurler’s Syndrome
14.7.6.3.8. Others
14.7.6.4.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
14.7.6.4.1. Adults
14.7.6.4.2. Children
14.7.6.5.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
End User
14.7.6.5.1. Infusion Centers
14.7.6.5.2. Gaucher Disease Treatment Centers
14.7.6.5.3. Hospitals and Clinics
14.7.6.5.4. Others
14.7.6.6.
Nordic
Countries Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.6.6.1. Denmark
14.7.6.6.2. Finland
14.7.6.6.3. Iceland
14.7.6.6.4. Sweden
14.7.6.6.5. Norway
14.7.7. Benelux Union
14.7.7.1.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.7.1.1. Alglucerase alfa
14.7.7.1.2. Laronidase
14.7.7.1.3. Imiglucerase
14.7.7.1.4. Idursulfase
14.7.7.1.5. Velaglucerase alfa
14.7.7.1.6. Taliglucerase alfa
14.7.7.1.7. Asfotase alfa
14.7.7.1.8. Galsulfase
14.7.7.1.9. Pegademase
14.7.7.1.10. Pancreatic Enzymes
14.7.7.1.11. Others
14.7.7.2.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.7.2.1. Oral
14.7.7.2.2. Parenteral
14.7.7.3.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
14.7.7.3.1. Gaucher Disease
14.7.7.3.2. Â A1AT
Deficiency
14.7.7.3.3. ADA Deficiency
14.7.7.3.4. Fabry
14.7.7.3.5. Â Pompe
14.7.7.3.6. Mucopolysaccharidosis
14.7.7.3.6.1. MPS 1
14.7.7.3.6.2. MSP II
14.7.7.3.6.3. MPS IVA
14.7.7.3.6.4. MPS VI
14.7.7.3.6.5. MPS VII
14.7.7.3.7. Hurler’s Syndrome
14.7.7.3.8. Others
14.7.7.4.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
14.7.7.4.1. Adults
14.7.7.4.2. Children
14.7.7.5.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
14.7.7.5.1. Infusion Centers
14.7.7.5.2. Gaucher Disease Treatment Centers
14.7.7.5.3. Hospitals and Clinics
14.7.7.5.4. Others
14.7.7.6.
Benelux
Union Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
14.7.7.6.1. Belgium
14.7.7.6.2. The Netherlands
14.7.7.6.3. Luxembourg
14.7.8. Rest of Europe
14.7.8.1.
Rest of
Europe Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
14.7.8.1.1. Alglucerase alfa
14.7.8.1.2. Laronidase
14.7.8.1.3. Imiglucerase
14.7.8.1.4. Idursulfase
14.7.8.1.5. Velaglucerase alfa
14.7.8.1.6. Taliglucerase alfa
14.7.8.1.7. Asfotase alfa
14.7.8.1.8. Galsulfase
14.7.8.1.9. Pegademase
14.7.8.1.10. Pancreatic Enzymes
14.7.8.1.11. Others
14.7.8.2.
Rest of
Europe Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
14.7.8.2.1. Oral
14.7.8.2.2. Parenteral
14.7.8.3.
Rest of
Europe Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
14.7.8.3.1. Gaucher Disease
14.7.8.3.2. Â A1AT
Deficiency
14.7.8.3.3. ADA Deficiency
14.7.8.3.4. Fabry
14.7.8.3.5. Â Pompe
14.7.8.3.6. Mucopolysaccharidosis
14.7.8.3.6.1. MPS 1
14.7.8.3.6.2. MSP II
14.7.8.3.6.3. MPS IVA
14.7.8.3.6.4. MPS VI
14.7.8.3.6.5. MPS VII
14.7.8.3.7. Hurler’s Syndrome
14.7.8.3.8. Others
14.7.8.4.
Rest of
Europe Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
14.7.8.4.1. Adults
14.7.8.4.2. Children
14.7.8.5.
Rest of
Europe Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
14.7.8.5.1. Infusion Centers
14.7.8.5.2. Gaucher Disease Treatment Centers
14.7.8.5.3. Hospitals and Clinics
14.7.8.5.4. Others
14.8. Key Segment for Channeling Investments
14.8.1. By Country
14.8.2. By Drug
14.8.3. By Route of Administration
14.8.4. By Disease
14.8.5. By Demography
14.8.6. By End User
15. Asia Pacific Enzyme Replacement Therapy
Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn)
15.2. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
15.2.1. Alglucerase alfa
15.2.2. Laronidase
15.2.3. Imiglucerase
15.2.4. Idursulfase
15.2.5. Velaglucerase alfa
15.2.6. Taliglucerase alfa
15.2.7. Asfotase alfa
15.2.8. Galsulfase
15.2.9. Pegademase
15.2.10. Pancreatic Enzymes
15.2.11. Others
15.3. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.3.1. Oral
15.3.2. Parenteral
15.4. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Disease
15.4.1. Gaucher Disease
15.4.2. Â A1AT
Deficiency
15.4.3. ADA Deficiency
15.4.4. Fabry
15.4.5. Â Pompe
15.4.6. Mucopolysaccharidosis
15.4.6.1.
MPS 1
15.4.6.2.
MSP II
15.4.6.3.
MPS IVA
15.4.6.4.
MPS VI
15.4.6.5.
MPS VII
15.4.7. Hurler’s Syndrome
15.4.8. Others
15.5. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Demography
15.5.1. Adults
15.5.2. Children
15.6. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By End User
15.6.1. Infusion Centers
15.6.2. Gaucher Disease Treatment Centers
15.6.3. Hospitals and Clinics
15.6.4. Others
15.7. Asia Pacific Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
15.7.1. China
15.7.1.1.
China
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.1.1.1. Alglucerase alfa
15.7.1.1.2. Laronidase
15.7.1.1.3. Imiglucerase
15.7.1.1.4. Idursulfase
15.7.1.1.5. Velaglucerase alfa
15.7.1.1.6. Taliglucerase alfa
15.7.1.1.7. Asfotase alfa
15.7.1.1.8. Galsulfase
15.7.1.1.9. Pegademase
15.7.1.1.10. Pancreatic Enzymes
15.7.1.1.11. Others
15.7.1.2.
China
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.1.2.1. Oral
15.7.1.2.2. Parenteral
15.7.1.3.
China
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
15.7.1.3.1. Gaucher Disease
15.7.1.3.2. Â A1AT
Deficiency
15.7.1.3.3. ADA Deficiency
15.7.1.3.4. Fabry
15.7.1.3.5. Â Pompe
15.7.1.3.6. Mucopolysaccharidosis
15.7.1.3.6.1. MPS 1
15.7.1.3.6.2. MSP II
15.7.1.3.6.3. MPS IVA
15.7.1.3.6.4. MPS VI
15.7.1.3.6.5. MPS VII
15.7.1.3.7. Hurler’s Syndrome
15.7.1.3.8. Others
15.7.1.4.
China
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
15.7.1.4.1. Adults
15.7.1.4.2. Children
15.7.1.5.
China
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
15.7.1.5.1. Infusion Centers
15.7.1.5.2. Gaucher Disease Treatment Centers
15.7.1.5.3. Hospitals and Clinics
15.7.1.5.4. Others
15.7.2. Japan
15.7.2.1.
Japan
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.2.1.1. Alglucerase alfa
15.7.2.1.2. Laronidase
15.7.2.1.3. Imiglucerase
15.7.2.1.4. Idursulfase
15.7.2.1.5. Velaglucerase alfa
15.7.2.1.6. Taliglucerase alfa
15.7.2.1.7. Asfotase alfa
15.7.2.1.8. Galsulfase
15.7.2.1.9. Pegademase
15.7.2.1.10. Pancreatic Enzymes
15.7.2.1.11. Others
15.7.2.2.
Japan
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.2.2.1. Oral
15.7.2.2.2. Parenteral
15.7.2.3.
Japan
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
15.7.2.3.1. Gaucher Disease
15.7.2.3.2. Â A1AT
Deficiency
15.7.2.3.3. ADA Deficiency
15.7.2.3.4. Fabry
15.7.2.3.5. Â Pompe
15.7.2.3.6. Mucopolysaccharidosis
15.7.2.3.6.1. MPS 1
15.7.2.3.6.2. MSP II
15.7.2.3.6.3. MPS IVA
15.7.2.3.6.4. MPS VI
15.7.2.3.6.5. MPS VII
15.7.2.3.7. Hurler’s Syndrome
15.7.2.3.8. Others
15.7.2.4.
Japan
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
15.7.2.4.1. Adults
15.7.2.4.2. Children
15.7.2.5.
Japan
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
15.7.2.5.1. Infusion Centers
15.7.2.5.2. Gaucher Disease Treatment Centers
15.7.2.5.3. Hospitals and Clinics
15.7.2.5.4. Others
15.7.3. India
15.7.3.1.
India
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.3.1.1. Alglucerase alfa
15.7.3.1.2. Laronidase
15.7.3.1.3. Imiglucerase
15.7.3.1.4. Idursulfase
15.7.3.1.5. Velaglucerase alfa
15.7.3.1.6. Taliglucerase alfa
15.7.3.1.7. Asfotase alfa
15.7.3.1.8. Galsulfase
15.7.3.1.9. Pegademase
15.7.3.1.10. Pancreatic Enzymes
15.7.3.1.11. Others
15.7.3.2.
India
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
15.7.3.2.1. Oral
15.7.3.2.2. Parenteral
15.7.3.3.
India
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
15.7.3.3.1. Gaucher Disease
15.7.3.3.2. Â A1AT
Deficiency
15.7.3.3.3. ADA Deficiency
15.7.3.3.4. Fabry
15.7.3.3.5. Â Pompe
15.7.3.3.6. Mucopolysaccharidosis
15.7.3.3.6.1. MPS 1
15.7.3.3.6.2. MSP II
15.7.3.3.6.3. MPS IVA
15.7.3.3.6.4. MPS VI
15.7.3.3.6.5. MPS VII
15.7.3.3.7. Hurler’s Syndrome
15.7.3.3.8. Others
15.7.3.4.
India
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
15.7.3.4.1. Adults
15.7.3.4.2. Children
15.7.3.5.
India
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
15.7.3.5.1. Infusion Centers
15.7.3.5.2. Gaucher Disease Treatment Centers
15.7.3.5.3. Hospitals and Clinics
15.7.3.5.4. Others
15.7.4. New Zealand
15.7.4.1.
New
Zealand Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
15.7.4.1.1. Alglucerase alfa
15.7.4.1.2. Laronidase
15.7.4.1.3. Imiglucerase
15.7.4.1.4. Idursulfase
15.7.4.1.5. Velaglucerase alfa
15.7.4.1.6. Taliglucerase alfa
15.7.4.1.7. Asfotase alfa
15.7.4.1.8. Galsulfase
15.7.4.1.9. Pegademase
15.7.4.1.10. Pancreatic Enzymes
15.7.4.1.11. Others
15.7.4.2.
New
Zealand Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.4.2.1. Oral
15.7.4.2.2. Parenteral
15.7.4.3.
New
Zealand Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
15.7.4.3.1. Gaucher Disease
15.7.4.3.2. Â A1AT
Deficiency
15.7.4.3.3. ADA Deficiency
15.7.4.3.4. Fabry
15.7.4.3.5. Â Pompe
15.7.4.3.6. Mucopolysaccharidosis
15.7.4.3.6.1. MPS 1
15.7.4.3.6.2. MSP II
15.7.4.3.6.3. MPS IVA
15.7.4.3.6.4. MPS VI
15.7.4.3.6.5. MPS VII
15.7.4.3.7. Hurler’s Syndrome
15.7.4.3.8. Others
15.7.4.4.
New
Zealand Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
15.7.4.4.1. Adults
15.7.4.4.2. Children
15.7.4.5.
New
Zealand Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
End User
15.7.4.5.1. Infusion Centers
15.7.4.5.2. Gaucher Disease Treatment Centers
15.7.4.5.3. Hospitals and Clinics
15.7.4.5.4. Others
15.7.5. Australia
15.7.5.1.
Australia
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.5.1.1. Alglucerase alfa
15.7.5.1.2. Laronidase
15.7.5.1.3. Imiglucerase
15.7.5.1.4. Idursulfase
15.7.5.1.5. Velaglucerase alfa
15.7.5.1.6. Taliglucerase alfa
15.7.5.1.7. Asfotase alfa
15.7.5.1.8. Galsulfase
15.7.5.1.9. Pegademase
15.7.5.1.10. Pancreatic Enzymes
15.7.5.1.11. Others
15.7.5.2.
Australia
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
15.7.5.2.1. Oral
15.7.5.2.2. Parenteral
15.7.5.3.
Australia
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
15.7.5.3.1. Gaucher Disease
15.7.5.3.2. Â A1AT
Deficiency
15.7.5.3.3. ADA Deficiency
15.7.5.3.4. Fabry
15.7.5.3.5. Â Pompe
15.7.5.3.6. Mucopolysaccharidosis
15.7.5.3.6.1. MPS 1
15.7.5.3.6.2. MSP II
15.7.5.3.6.3. MPS IVA
15.7.5.3.6.4. MPS VI
15.7.5.3.6.5. MPS VII
15.7.5.3.7. Hurler’s Syndrome
15.7.5.3.8. Others
15.7.5.4.
Australia
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
15.7.5.4.1. Adults
15.7.5.4.2. Children
15.7.5.5.
Australia
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
15.7.5.5.1. Infusion Centers
15.7.5.5.2. Gaucher Disease Treatment Centers
15.7.5.5.3. Hospitals and Clinics
15.7.5.5.4. Others
15.7.6. South Korea
15.7.6.1.
South
Korea Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.6.1.1. Alglucerase alfa
15.7.6.1.2. Laronidase
15.7.6.1.3. Imiglucerase
15.7.6.1.4. Idursulfase
15.7.6.1.5. Velaglucerase alfa
15.7.6.1.6. Taliglucerase alfa
15.7.6.1.7. Asfotase alfa
15.7.6.1.8. Galsulfase
15.7.6.1.9. Pegademase
15.7.6.1.10. Pancreatic Enzymes
15.7.6.1.11. Others
15.7.6.2.
South
Korea Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
15.7.6.2.1. Oral
15.7.6.2.2. Parenteral
15.7.6.3.
South
Korea Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
15.7.6.3.1. Gaucher Disease
15.7.6.3.2. Â A1AT
Deficiency
15.7.6.3.3. ADA Deficiency
15.7.6.3.4. Fabry
15.7.6.3.5. Â Pompe
15.7.6.3.6. Mucopolysaccharidosis
15.7.6.3.6.1. MPS 1
15.7.6.3.6.2. MSP II
15.7.6.3.6.3. MPS IVA
15.7.6.3.6.4. MPS VI
15.7.6.3.6.5. MPS VII
15.7.6.3.7. Hurler’s Syndrome
15.7.6.3.8. Others
15.7.6.4.
South
Korea Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
15.7.6.4.1. Adults
15.7.6.4.2. Children
15.7.6.5.
South
Korea Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.6.5.1. Infusion Centers
15.7.6.5.2. Gaucher Disease Treatment Centers
15.7.6.5.3. Hospitals and Clinics
15.7.6.5.4. Others
15.7.7. Southeast Asia
15.7.7.1.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
15.7.7.1.1. Alglucerase alfa
15.7.7.1.2. Laronidase
15.7.7.1.3. Imiglucerase
15.7.7.1.4. Idursulfase
15.7.7.1.5. Velaglucerase alfa
15.7.7.1.6. Taliglucerase alfa
15.7.7.1.7. Asfotase alfa
15.7.7.1.8. Galsulfase
15.7.7.1.9. Pegademase
15.7.7.1.10. Pancreatic Enzymes
15.7.7.1.11. Others
15.7.7.2.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route
of Administration
15.7.7.2.1. Oral
15.7.7.2.2. Parenteral
15.7.7.3.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
15.7.7.3.1. Gaucher Disease
15.7.7.3.2. Â A1AT
Deficiency
15.7.7.3.3. ADA Deficiency
15.7.7.3.4. Fabry
15.7.7.3.5. Â Pompe
15.7.7.3.6. Mucopolysaccharidosis
15.7.7.3.6.1. MPS 1
15.7.7.3.6.2. MSP II
15.7.7.3.6.3. MPS IVA
15.7.7.3.6.4. MPS VI
15.7.7.3.6.5. MPS VII
15.7.7.3.7. Hurler’s Syndrome
15.7.7.3.8. Others
15.7.7.4.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
15.7.7.4.1. Adults
15.7.7.4.2. Children
15.7.7.5.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
15.7.7.5.1. Infusion Centers
15.7.7.5.2. Gaucher Disease Treatment Centers
15.7.7.5.3. Hospitals and Clinics
15.7.7.5.4. Others
15.7.7.6.
Southeast
Asia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Country
15.7.7.6.1. Indonesia
15.7.7.6.2. Thailand
15.7.7.6.3. Malaysia
15.7.7.6.4. Singapore
15.7.7.6.5. Rest of Southeast Asia
15.7.8. Rest of Asia Pacific
15.7.8.1.
Rest of
Asia Pacific Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Drug
15.7.8.1.1. Alglucerase alfa
15.7.8.1.2. Laronidase
15.7.8.1.3. Imiglucerase
15.7.8.1.4. Idursulfase
15.7.8.1.5. Velaglucerase alfa
15.7.8.1.6. Taliglucerase alfa
15.7.8.1.7. Asfotase alfa
15.7.8.1.8. Galsulfase
15.7.8.1.9. Pegademase
15.7.8.1.10. Pancreatic Enzymes
15.7.8.1.11. Others
15.7.8.2.
Rest of
Asia Pacific Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
15.7.8.2.1. Oral
15.7.8.2.2. Parenteral
15.7.8.3.
Rest of
Asia Pacific Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Disease
15.7.8.3.1. Gaucher Disease
15.7.8.3.2. Â A1AT
Deficiency
15.7.8.3.3. ADA Deficiency
15.7.8.3.4. Fabry
15.7.8.3.5. Â Pompe
15.7.8.3.6. Mucopolysaccharidosis
15.7.8.3.6.1. MPS 1
15.7.8.3.6.2. MSP II
15.7.8.3.6.3. MPS IVA
15.7.8.3.6.4. MPS VI
15.7.8.3.6.5. MPS VII
15.7.8.3.7. Hurler’s Syndrome
15.7.8.3.8. Others
15.7.8.4.
Rest of
Asia Pacific Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Demography
15.7.8.4.1. Adults
15.7.8.4.2. Children
15.7.8.5.
Rest of
Asia Pacific Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By End User
15.7.8.5.1. Infusion Centers
15.7.8.5.2. Gaucher Disease Treatment Centers
15.7.8.5.3. Hospitals and Clinics
15.7.8.5.4. Others
15.8. Key Segment for Channeling Investments
15.8.1. By Country
15.8.2. By Drug
15.8.3. By Route of Administration
15.8.4. By Disease
15.8.5. By Demography
15.8.6. By End User
16. Middle East and Africa Enzyme Replacement
Therapy Market Analysis and Forecasts, 2022 - 2030
16.1. Overview
16.1.1. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn)
16.2. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.2.1. Alglucerase alfa
16.2.2. Laronidase
16.2.3. Imiglucerase
16.2.4. Idursulfase
16.2.5. Velaglucerase alfa
16.2.6. Taliglucerase alfa
16.2.7. Asfotase alfa
16.2.8. Galsulfase
16.2.9. Pegademase
16.2.10. Pancreatic Enzymes
16.2.11. Others
16.3. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By Route of Administration
16.3.1. Oral
16.3.2. Parenteral
16.4. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
16.4.1. Gaucher Disease
16.4.2. Â A1AT
Deficiency
16.4.3. ADA Deficiency
16.4.4. Fabry
16.4.5. Â Pompe
16.4.6. Mucopolysaccharidosis
16.4.6.1.
MPS 1
16.4.6.2.
MSP II
16.4.6.3.
MPS IVA
16.4.6.4.
MPS VI
16.4.6.5.
MPS VII
16.4.7. Hurler’s Syndrome
16.4.8. Others
16.5. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
16.5.1. Adults
16.5.2. Children
16.6. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By End User
16.6.1. Infusion Centers
16.6.2. Gaucher Disease Treatment Centers
16.6.3. Hospitals and Clinics
16.6.4. Others
16.7. Middle East and Africa Enzyme Replacement
Therapy Market Revenue (US$ Mn) and Forecasts, By Country
16.7.1. Saudi Arabia
16.7.1.1.
Saudi
Arabia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
16.7.1.1.1. Alglucerase alfa
16.7.1.1.2. Laronidase
16.7.1.1.3. Imiglucerase
16.7.1.1.4. Idursulfase
16.7.1.1.5. Velaglucerase alfa
16.7.1.1.6. Taliglucerase alfa
16.7.1.1.7. Asfotase alfa
16.7.1.1.8. Galsulfase
16.7.1.1.9. Pegademase
16.7.1.1.10. Pancreatic Enzymes
16.7.1.1.11. Others
16.7.1.2.
Saudi
Arabia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.1.2.1. Oral
16.7.1.2.2. Parenteral
16.7.1.3.
Saudi
Arabia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
16.7.1.3.1. Gaucher Disease
16.7.1.3.2. Â A1AT
Deficiency
16.7.1.3.3. ADA Deficiency
16.7.1.3.4. Fabry
16.7.1.3.5. Â Pompe
16.7.1.3.6. Mucopolysaccharidosis
16.7.1.3.6.1. MPS 1
16.7.1.3.6.2. MSP II
16.7.1.3.6.3. MPS IVA
16.7.1.3.6.4. MPS VI
16.7.1.3.6.5. MPS VII
16.7.1.3.7. Hurler’s Syndrome
16.7.1.3.8. Others
16.7.1.4.
Saudi
Arabia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
16.7.1.4.1. Adults
16.7.1.4.2. Children
16.7.1.5.
Saudi
Arabia Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
16.7.1.5.1. Infusion Centers
16.7.1.5.2. Gaucher Disease Treatment Centers
16.7.1.5.3. Hospitals and Clinics
16.7.1.5.4. Others
16.7.2. UAE
16.7.2.1.
UAE
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.2.1.1. Alglucerase alfa
16.7.2.1.2. Laronidase
16.7.2.1.3. Imiglucerase
16.7.2.1.4. Idursulfase
16.7.2.1.5. Velaglucerase alfa
16.7.2.1.6. Taliglucerase alfa
16.7.2.1.7. Asfotase alfa
16.7.2.1.8. Galsulfase
16.7.2.1.9. Pegademase
16.7.2.1.10. Pancreatic Enzymes
16.7.2.1.11. Others
16.7.2.2.
UAE
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.2.2.1. Oral
16.7.2.2.2. Parenteral
16.7.2.3.
UAE
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
16.7.2.3.1. Gaucher Disease
16.7.2.3.2. Â A1AT
Deficiency
16.7.2.3.3. ADA Deficiency
16.7.2.3.4. Fabry
16.7.2.3.5. Â Pompe
16.7.2.3.6. Mucopolysaccharidosis
16.7.2.3.6.1. MPS 1
16.7.2.3.6.2. MSP II
16.7.2.3.6.3. MPS IVA
16.7.2.3.6.4. MPS VI
16.7.2.3.6.5. MPS VII
16.7.2.3.7. Hurler’s Syndrome
16.7.2.3.8. Others
16.7.2.4.
UAE
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
16.7.2.4.1. Adults
16.7.2.4.2. Children
16.7.2.5.
UAE
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
16.7.2.5.1. Infusion Centers
16.7.2.5.2. Gaucher Disease Treatment Centers
16.7.2.5.3. Hospitals and Clinics
16.7.2.5.4. Others
16.7.3. Egypt
16.7.3.1.
Egypt
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.3.1.1. Alglucerase alfa
16.7.3.1.2. Laronidase
16.7.3.1.3. Imiglucerase
16.7.3.1.4. Idursulfase
16.7.3.1.5. Velaglucerase alfa
16.7.3.1.6. Taliglucerase alfa
16.7.3.1.7. Asfotase alfa
16.7.3.1.8. Galsulfase
16.7.3.1.9. Pegademase
16.7.3.1.10. Pancreatic Enzymes
16.7.3.1.11. Others
16.7.3.2.
Egypt
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.3.2.1. Oral
16.7.3.2.2. Parenteral
16.7.3.3.
Egypt
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
16.7.3.3.1. Gaucher Disease
16.7.3.3.2. Â A1AT
Deficiency
16.7.3.3.3. ADA Deficiency
16.7.3.3.4. Fabry
16.7.3.3.5. Â Pompe
16.7.3.3.6. Mucopolysaccharidosis
16.7.3.3.6.1. MPS 1
16.7.3.3.6.2. MSP II
16.7.3.3.6.3. MPS IVA
16.7.3.3.6.4. MPS VI
16.7.3.3.6.5. MPS VII
16.7.3.3.7. Hurler’s Syndrome
16.7.3.3.8. Others
16.7.3.4.
Egypt
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
16.7.3.4.1. Adults
16.7.3.4.2. Children
16.7.3.5.
Egypt
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
16.7.3.5.1. Infusion Centers
16.7.3.5.2. Gaucher Disease Treatment Centers
16.7.3.5.3. Hospitals and Clinics
16.7.3.5.4. Others
16.7.4. Kuwait
16.7.4.1.
Kuwait
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
16.7.4.1.1. Alglucerase alfa
16.7.4.1.2. Laronidase
16.7.4.1.3. Imiglucerase
16.7.4.1.4. Idursulfase
16.7.4.1.5. Velaglucerase alfa
16.7.4.1.6. Taliglucerase alfa
16.7.4.1.7. Asfotase alfa
16.7.4.1.8. Galsulfase
16.7.4.1.9. Pegademase
16.7.4.1.10. Pancreatic Enzymes
16.7.4.1.11. Others
16.7.4.2.
Kuwait
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
16.7.4.2.1. Oral
16.7.4.2.2. Parenteral
16.7.4.3.
Kuwait
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
16.7.4.3.1. Gaucher Disease
16.7.4.3.2. Â A1AT
Deficiency
16.7.4.3.3. ADA Deficiency
16.7.4.3.4. Fabry
16.7.4.3.5. Â Pompe
16.7.4.3.6. Mucopolysaccharidosis
16.7.4.3.6.1. MPS 1
16.7.4.3.6.2. MSP II
16.7.4.3.6.3. MPS IVA
16.7.4.3.6.4. MPS VI
16.7.4.3.6.5. MPS VII
16.7.4.3.7. Hurler’s Syndrome
16.7.4.3.8. Others
16.7.4.4.
Kuwait
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
16.7.4.4.1. Adults
16.7.4.4.2. Children
16.7.4.5.
Kuwait
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
16.7.4.5.1. Infusion Centers
16.7.4.5.2. Gaucher Disease Treatment Centers
16.7.4.5.3. Hospitals and Clinics
16.7.4.5.4. Others
16.7.5. South Africa
16.7.5.1.
South
Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Drug
16.7.5.1.1. Alglucerase alfa
16.7.5.1.2. Laronidase
16.7.5.1.3. Imiglucerase
16.7.5.1.4. Idursulfase
16.7.5.1.5. Velaglucerase alfa
16.7.5.1.6. Taliglucerase alfa
16.7.5.1.7. Asfotase alfa
16.7.5.1.8. Galsulfase
16.7.5.1.9. Pegademase
16.7.5.1.10. Pancreatic Enzymes
16.7.5.1.11. Others
16.7.5.2.
South
Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Route of Administration
16.7.5.2.1. Oral
16.7.5.2.2. Parenteral
16.7.5.3.
South
Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Disease
16.7.5.3.1. Gaucher Disease
16.7.5.3.2. Â A1AT
Deficiency
16.7.5.3.3. ADA Deficiency
16.7.5.3.4. Fabry
16.7.5.3.5. Â Pompe
16.7.5.3.6. Mucopolysaccharidosis
16.7.5.3.6.1. MPS 1
16.7.5.3.6.2. MSP II
16.7.5.3.6.3. MPS IVA
16.7.5.3.6.4. MPS VI
16.7.5.3.6.5. MPS VII
16.7.5.3.7. Hurler’s Syndrome
16.7.5.3.8. Others
16.7.5.4.
South
Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By
Demography
16.7.5.4.1. Adults
16.7.5.4.2. Children
16.7.5.5.
South
Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End
User
16.7.5.5.1. Infusion Centers
16.7.5.5.2. Gaucher Disease Treatment Centers
16.7.5.5.3. Hospitals and Clinics
16.7.5.5.4. Others
16.7.6. Rest of Middle East & Africa
16.7.6.1.
Rest of
Middle East & Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and
Forecasts, By Drug
16.7.6.1.1. Alglucerase alfa
16.7.6.1.2. Laronidase
16.7.6.1.3. Imiglucerase
16.7.6.1.4. Idursulfase
16.7.6.1.5. Velaglucerase alfa
16.7.6.1.6. Taliglucerase alfa
16.7.6.1.7. Asfotase alfa
16.7.6.1.8. Galsulfase
16.7.6.1.9. Pegademase
16.7.6.1.10. Pancreatic Enzymes
16.7.6.1.11. Others
16.7.6.2.
Rest of
Middle East & Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and
Forecasts, By Route of Administration
16.7.6.2.1. Oral
16.7.6.2.2. Parenteral
16.7.6.3.
Rest of
Middle East & Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and
Forecasts, By Disease
16.7.6.3.1. Gaucher Disease
16.7.6.3.2. Â A1AT
Deficiency
16.7.6.3.3. ADA Deficiency
16.7.6.3.4. Fabry
16.7.6.3.5. Â Pompe
16.7.6.3.6. Mucopolysaccharidosis
16.7.6.3.6.1. MPS 1
16.7.6.3.6.2. MSP II
16.7.6.3.6.3. MPS IVA
16.7.6.3.6.4. MPS VI
16.7.6.3.6.5. MPS VII
16.7.6.3.7. Hurler’s Syndrome
16.7.6.3.8. Others
16.7.6.4.
Rest of
Middle East & Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and
Forecasts, By Demography
16.7.6.4.1. Adults
16.7.6.4.2. Children
16.7.6.5.
Rest of
Middle East & Africa Enzyme Replacement Therapy Market Revenue (US$ Mn) and
Forecasts, By End User
16.7.6.5.1. Infusion Centers
16.7.6.5.2. Gaucher Disease Treatment Centers
16.7.6.5.3. Hospitals and Clinics
16.7.6.5.4. Others
16.8. Key Segment for Channeling Investments
16.8.1. By Country
16.8.2. By Drug
16.8.3. By Route of Administration
16.8.4. By Disease
16.8.5. By Demography
16.8.6. By End User
17. Latin America Enzyme Replacement Therapy
Market Analysis and Forecasts, 2022 - 2030
17.1. Overview
17.1.1. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn)
17.2. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Drug
17.2.1. Alglucerase alfa
17.2.2. Laronidase
17.2.3. Imiglucerase
17.2.4. Idursulfase
17.2.5. Velaglucerase alfa
17.2.6. Taliglucerase alfa
17.2.7. Asfotase alfa
17.2.8. Galsulfase
17.2.9. Pegademase
17.2.10. Pancreatic Enzymes
17.2.11. Others
17.3. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Route of Administration
17.3.1. Oral
17.3.2. Parenteral
17.4. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Disease
17.4.1. Gaucher Disease
17.4.2. Â A1AT
Deficiency
17.4.3. ADA Deficiency
17.4.4. Fabry
17.4.5. Â Pompe
17.4.6. Mucopolysaccharidosis
17.4.6.1.
MPS 1
17.4.6.2.
MSP II
17.4.6.3.
MPS IVA
17.4.6.4.
MPS VI
17.4.6.5.
MPS VII
17.4.7. Hurler’s Syndrome
17.4.8. Others
17.5. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Demography
17.5.1. Adults
17.5.2. Children
17.6. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By End User
17.6.1. Infusion Centers
17.6.2. Gaucher Disease Treatment Centers
17.6.3. Hospitals and Clinics
17.6.4. Others
17.7. Latin America Enzyme Replacement Therapy
Market Revenue (US$ Mn) and Forecasts, By Country
17.7.1. Brazil
17.7.1.1.
Brazil
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.1.1.1. Alglucerase alfa
17.7.1.1.2. Laronidase
17.7.1.1.3. Imiglucerase
17.7.1.1.4. Idursulfase
17.7.1.1.5. Velaglucerase alfa
17.7.1.1.6. Taliglucerase alfa
17.7.1.1.7. Asfotase alfa
17.7.1.1.8. Galsulfase
17.7.1.1.9. Pegademase
17.7.1.1.10. Pancreatic Enzymes
17.7.1.1.11. Others
17.7.1.2.
Brazil
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.1.2.1. Oral
17.7.1.2.2. Parenteral
17.7.1.3.
Brazil
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
17.7.1.3.1. Gaucher Disease
17.7.1.3.2. Â A1AT
Deficiency
17.7.1.3.3. ADA Deficiency
17.7.1.3.4. Fabry
17.7.1.3.5. Â Pompe
17.7.1.3.6. Mucopolysaccharidosis
17.7.1.3.6.1. MPS 1
17.7.1.3.6.2. MSP II
17.7.1.3.6.3. MPS IVA
17.7.1.3.6.4. MPS VI
17.7.1.3.6.5. MPS VII
17.7.1.3.7. Hurler’s Syndrome
17.7.1.3.8. Others
17.7.1.4.
Brazil
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
17.7.1.4.1. Adults
17.7.1.4.2. Children
17.7.1.5.
Brazil
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
17.7.1.5.1. Infusion Centers
17.7.1.5.2. Gaucher Disease Treatment Centers
17.7.1.5.3. Hospitals and Clinics
17.7.1.5.4. Others
17.7.2. Argentina
17.7.2.1.
Argentina
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Drug
17.7.2.1.1. Alglucerase alfa
17.7.2.1.2. Laronidase
17.7.2.1.3. Imiglucerase
17.7.2.1.4. Idursulfase
17.7.2.1.5. Velaglucerase alfa
17.7.2.1.6. Taliglucerase alfa
17.7.2.1.7. Asfotase alfa
17.7.2.1.8. Galsulfase
17.7.2.1.9. Pegademase
17.7.2.1.10. Pancreatic Enzymes
17.7.2.1.11. Others
17.7.2.2.
Argentina
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Route of
Administration
17.7.2.2.1. Oral
17.7.2.2.2. Parenteral
17.7.2.3.
Argentina
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Disease
17.7.2.3.1. Gaucher Disease
17.7.2.3.2. Â A1AT
Deficiency
17.7.2.3.3. ADA Deficiency
17.7.2.3.4. Fabry
17.7.2.3.5. Â Pompe
17.7.2.3.6. Mucopolysaccharidosis
17.7.2.3.6.1. MPS 1
17.7.2.3.6.2. MSP II
17.7.2.3.6.3. MPS IVA
17.7.2.3.6.4. MPS VI
17.7.2.3.6.5. MPS VII
17.7.2.3.7. Hurler’s Syndrome
17.7.2.3.8. Others
17.7.2.4.
Argentina
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By Demography
17.7.2.4.1. Adults
17.7.2.4.2. Children
17.7.2.5.
Argentina
Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts, By End User
17.7.2.5.1. Infusion Centers
17.7.2.5.2. Gaucher Disease Treatment Centers
17.7.2.5.3. Hospitals and Clinics
17.7.2.5.4. Others
17.7.3. Rest of Latin America
17.7.3.1.
Rest of
Latin America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Drug
17.7.3.1.1. Alglucerase alfa
17.7.3.1.2. Laronidase
17.7.3.1.3. Imiglucerase
17.7.3.1.4. Idursulfase
17.7.3.1.5. Velaglucerase alfa
17.7.3.1.6. Taliglucerase alfa
17.7.3.1.7. Asfotase alfa
17.7.3.1.8. Galsulfase
17.7.3.1.9. Pegademase
17.7.3.1.10. Pancreatic Enzymes
17.7.3.1.11. Others
17.7.3.2.
Rest of
Latin America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Route of Administration
17.7.3.2.1. Oral
17.7.3.2.2. Parenteral
17.7.3.3.
Rest of
Latin America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Disease
17.7.3.3.1. Gaucher Disease
17.7.3.3.2. Â A1AT
Deficiency
17.7.3.3.3. ADA Deficiency
17.7.3.3.4. Fabry
17.7.3.3.5. Â Pompe
17.7.3.3.6. Mucopolysaccharidosis
17.7.3.3.6.1. MPS 1
17.7.3.3.6.2. MSP II
17.7.3.3.6.3. MPS IVA
17.7.3.3.6.4. MPS VI
17.7.3.3.6.5. MPS VII
17.7.3.3.7. Hurler’s Syndrome
17.7.3.3.8. Others
17.7.3.4.
Rest of
Latin America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By Demography
17.7.3.4.1. Adults
17.7.3.4.2. Children
17.7.3.5.
Rest of
Latin America Enzyme Replacement Therapy Market Revenue (US$ Mn) and Forecasts,
By End User
17.7.3.5.1. Infusion Centers
17.7.3.5.2. Gaucher Disease Treatment Centers
17.7.3.5.3. Hospitals and Clinics
17.7.3.5.4. Others
17.8. Key Segment for Channeling Investments
17.8.1. By Country
17.8.2. By Drug
17.8.3. By Route of Administration
17.8.4. By Disease
17.8.5. By Demography
17.8.6. By End User
18. Competitive Benchmarking
18.1. Brand Benchmarking
18.2. Market Share Analysis, 2021
18.3. Global Presence and Growth Strategies
18.3.1. Mergers and Acquisitions
18.3.2. Product Launches
18.3.3. Investments Trends
18.3.4. R&D Initiatives
19. Player Profiles
19.1. AbbVie Inc.
19.1.1. Company Details
19.1.2. Company Overview
19.1.3. Product Offerings
19.1.4. Key Developments
19.1.5. Financial Analysis
19.1.6. SWOT Analysis
19.1.7. Business Strategies
19.2. Amicus Therapeutics, Inc
19.2.1. Company Details
19.2.2. Company Overview
19.2.3. Product Offerings
19.2.4. Key Developments
19.2.5. Financial Analysis
19.2.6. SWOT Analysis
19.2.7. Business Strategies
19.3. BioMarin
19.3.1. Company Details
19.3.2. Company Overview
19.3.3. Product Offerings
19.3.4. Key Developments
19.3.5. Financial Analysis
19.3.6. SWOT Analysis
19.3.7. Business Strategies
19.4. CHIESI Farmaceutici S.p.A.
19.4.1. Company Details
19.4.2. Company Overview
19.4.3. Product Offerings
19.4.4. Key Developments
19.4.5. Financial Analysis
19.4.6. SWOT Analysis
19.4.7. Business Strategies
19.5. Digestive Care, Inc.
19.5.1. Company Details
19.5.2. Company Overview
19.5.3. Product Offerings
19.5.4. Key Developments
19.5.5. Financial Analysis
19.5.6. SWOT Analysis
19.5.7. Business Strategies
19.6. Leadiant Biosciences, Inc.
19.6.1. Company Details
19.6.2. Company Overview
19.6.3. Product Offerings
19.6.4. Key Developments
19.6.5. Financial Analysis
19.6.6. SWOT Analysis
19.6.7. Business Strategies
19.7. Nestle Health Science
19.7.1. Company Details
19.7.2. Company Overview
19.7.3. Product Offerings
19.7.4. Key Developments
19.7.5. Financial Analysis
19.7.6. SWOT Analysis
19.7.7. Business Strategies
19.8. Pfizer Inc.
19.8.1. Company Details
19.8.2. Company Overview
19.8.3. Product Offerings
19.8.4. Key Developments
19.8.5. Financial Analysis
19.8.6. SWOT Analysis
19.8.7. Business Strategies
19.9. Protalix
19.9.1. Company Details
19.9.2. Company Overview
19.9.3. Product Offerings
19.9.4. Key Developments
19.9.5. Financial Analysis
19.9.6. SWOT Analysis
19.9.7. Business Strategies
19.10. Sanofi
19.10.1. Company Details
19.10.2. Company Overview
19.10.3. Product Offerings
19.10.4. Key Developments
19.10.5. Financial Analysis
19.10.6. SWOT Analysis
19.10.7. Business Strategies
19.11. Takeda Pharmaceutical Company Limited
19.11.1. Company Details
19.11.2. Company Overview
19.11.3. Product Offerings
19.11.4. Key Developments
19.11.5. Financial Analysis
19.11.6. SWOT Analysis
19.11.7. Business Strategies
19.12. Other Market Participants
20. Key Findings
Note: This ToC is tentative and
can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.